Search results
Results from the WOW.Com Content Network
T cells are one of the important types of white blood cells of the immune system and play a central role in the adaptive immune response. T cells can be distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on their cell surface. T cells are born from hematopoietic stem cells, [1] found in the bone marrow.
In 1991, three groups reported discovering CD154, which is the molecular basis of T cell helper function. Seth Lederman at Columbia University generated a murine monoclonal antibody, 5c8 that inhibited contact-dependent T cell helper function in human cells which characterized the 32 kDa surface protein transiently expressed on CD4 + T cells. [16]
ICOS: This molecule, short for Inducible T-cell costimulator, and also called CD278, is expressed on activated T cells. Its ligand is ICOSL, expressed mainly on B cells and dendritic cells. The molecule seems to be important in T cell effector function. [26] The American biotechnology company Jounce Therapeutics is developing an ICOS agonist.
PTPRC is a critical enzyme involved in regulating immune cell function. PTPRC is a transmembrane protein tyrosine phosphatase expressed on the surface of all nucleated hematopoietic cells, particularly lymphocytes. It plays a key role in the activation and differentiation of T cells, B cells, and other immune cells by modulating signaling pathways.
CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). [1] It is composed of four distinct chains. In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains.
CTLA-4 is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells. CTLA-4 is homologous to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA-4 binds CD80 and CD86 with ...
Compared to a normal antigen-induced T-cell response where 0.0001–0.001% of the body's T-cells are activated, these SAgs are capable of activating up to 20% of the body's T-cells. [3] Furthermore, Anti- CD3 and Anti- CD28 antibodies ( CD28-SuperMAB ) have also shown to be highly potent superantigens (and can activate up to 100% of T cells).
Subsequently, the primed cells will differentiate either into effector cells or into memory cells that can mount stronger and faster response to second and upcoming immune challenges. [2] T and B cell priming occurs in the secondary lymphoid organs (lymph nodes and spleen). Priming of naïve T cells requires dendritic cell antigen presentation.